• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Hologic inks $125 million deal for Interlace Medical

Hologic inks $125 million deal for Interlace Medical

January 7, 2011 By MassDevice staff

HOLX, Interlace logos

Hologic Inc. (NSDQ:HOLX) acquired Interlace Medical Inc. and its minimally invasive fibroid treatment for $125 million, saying it hopes to have Interlace’s MyoSure system on the market early this year.

The Bedford, Mass.-based women’s health player said it plans to integrate its neighbor from nearby Framingham into its gynecological surgery division. Hologic said it will pay $125 million in cash, "subject to adjustment," and two annual contingent payments, payable as cash based on a multiple of incremental revenue growth.

The MyoSure device is a hysteroscopic system designed to remove fibroids — benign tumors of the uterus — in an out-patient procedure, using a high-speed cutting blade capable of removing a three-centimeter fibroid in 10 minutes, according to a product brochure (PDF).

Interlace, which won 510(k) clearance for the system in October 2009, raised $21 million in June of last year in a Series C round aimed at commercializing the MyoSure system. The company also won a $75,000 tax break from the Mass. Life Sciences Center to foster the creation of 10 permanent life science jobs in the Bay State. In 2009, Interlace landed a $300,000 tax break from the Commonwealth.

In March 2010, the company launched a clinical trial of the MyoSure device, aiming to prove that women experience little pain or discomfort during the procedure.

Steve Williamson, general manager of Hologic’s gynecological surgery products arm, said the acquisition is a natural complement to the company’s suite of minimally invasive products. Hologic also makes the NovaSure endometrial ablation and Adiana female sterilization lines.

Hologic said it’s planning a campaign to train physicians on using the MyoSure system, with an eye toward having it fully integrated and under promotion "in early 2011."

A fibroid treatment isn’t the only thing Hologic gets in the deal. The company also inherits a lawsuit filed by Smith & Nephew plc (NYSE:SNN) against Interlace in June 2010. The suit alleges that the MyoSure system infringes one of the British conglomerate’s patents for an arthroscopic surgical instrument.

Filed Under: Business/Financial News, Endoscopic, Gynecological, News Well, Women's Health Tagged With: Hologic, Interlace Medical Inc.

More recent news

  • Cognixion, Blackrock Neurotech ink distro deal for BCI tech
  • AdvaMed calls for medtech tariff exemptions at Senate hearing
  • GE HealthCare, Raydiant Oximetry partner on fetal oxygen saturation tech
  • Terumo Neuro launches new stroke catheter in the U.S.
  • EnVVeno has first-in-human heart valve data, expects FDA decision this year

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy